NeoMed’s competitive advantage is its specialist healthcare investment strategy combined with its balanced portfolio approach and its strong footprint in Scandinavia and Switzerland.
NeoMed exclusively invests in emerging companies in the pharmaceutical, medical device and diagnostics industries. To implement this strategy, NeoMed has built strong specialist skills and network and thereby is competitively positioned to identify and develop the most promising companies in the healthcare industry.
NeoMed builds a balanced portfolio of 10 to 12 investments each with a target size of €5-10 million. With this investment range, NeoMed accesses the most promising opportunities, by investing as lead investor or as syndicate partner in competitive deals. With 10 to 12 portfolio companies, NeoMed also has the human resource to actively manage all its investments and successful realisations have a material impact on each fund’s returns.
Finally, NeoMed has a unique footprint in Scandinavia and Switzerland. These geographies represent large healthcare markets and have strong innovation, academic and clinical research and host large corporate healthcare activity.